Canopy Growth (CGC) Cash from Investing Activities (2019 - 2026)
Canopy Growth (CGC) posted Cash from Investing Activities of $15.3 million for Q4 2025, up 3101.35% sequentially from -$508807.3 in Q2 2025, and up 1645.86% YoY from $874704.2 in Q4 2024.
Canopy Growth (CGC) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Canopy Growth has reported Cash from Investing Activities for 7 years, with the latest figure at $15.3 million in Q4 2025.
- Quarterly Cash from Investing Activities rose 1645.86% year-over-year to $15.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.1 million (up 157.27% YoY) and the FY2026 annual result came in at -$15.6 million, up 53.26% from the prior year.
- Cash from Investing Activities advanced to $15.3 million in Q4 2025 per CGC's latest filing, from -$508807.3 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $260.8 million in Q3 2021 and troughed at -$438.7 million in Q1 2021.
- A 5-year average of $11.3 million and a median of $6.3 million in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2021 and 2025: Cash from Investing Activities slumped 788.29% in 2021, then soared 1645.86% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$19.7 million in 2021, then surged by 605.86% to $99.5 million in 2022, then plunged by 100.45% to -$448801.2 in 2023, then tumbled by 120.11% to -$987871.8 in 2024, then jumped by 1645.86% to $15.3 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $15.3 million, -$508807.3, and -$987871.8 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Canopy Growth | 434.93 Mn | 187.92 Mn | 16.08 Mn | -532,795.93 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -532,795.93 |
| Jun 30, 2026 | -532,795.93 |
| Dec 31, 2025 | 15.27 Mn |
| Dec 31, 2025 | 15.27 Mn |
| Jun 30, 2025 | -508,807.31 |
| Jun 30, 2025 | -508,807.31 |
| Dec 31, 2024 | -987,871.81 |
| Dec 31, 2024 | -987,871.81 |
| Sep 30, 2024 | -1.63 Mn |
| Sep 30, 2024 | -1.63 Mn |
| Jun 30, 2024 | -31.58 Mn |
| Jun 30, 2024 | -31.58 Mn |
| Mar 31, 2024 | 12.98 Mn |
| Mar 31, 2024 | 12.98 Mn |
| Dec 31, 2023 | -448,801.21 |
| Dec 31, 2023 | -448,801.21 |
| Sep 30, 2023 | 44.86 Mn |
| Sep 30, 2023 | 44.86 Mn |
| Jun 30, 2023 | 106.14 Mn |
| Jun 30, 2023 | 106.14 Mn |